The complexity of cancer chemotherapy requires pharmacists be familiar with the complicated regimens and highly toxic agents used. This column reviews various issues related to preparation, dispensing, and administration of antineoplastic therapy, and the agents, both commercially available and investigational, used to treat malignant diseases.
Get full access to this article
View all access options for this article.
References
1.
Pujade-LauraineE., WagnerU., Aavall-LundqvistE.Pegylated liposomal doxorubicin and carboplatin compared with paclitaxel and carboplatin for patients with platinum-sensitive ovarian cancer in late relapse. J Clin Oncol.2010; 28(20): 3323–3329.
2.
PignataS., ScambiaG., FerrandinaG.Carboplatin plus paclitaxel versus carboplatin plus pegylated liposomal doxorubicin as first-line treatment for patients with ovarian cancer: The MITO-2 randomized phase III trial. J Clin Oncol.2011; 20: 29(27): 3628–3635.
3.
FerreroJ.M., WeberB., GeayJ.F.Second-line chemotherapy with pegylated liposomal doxorubicin and carboplatin is highly effective in patients with advanced ovarian cancer in late relapse: A GINECO phase II trial. Ann Oncol.2007; 18(2): 263–268.
4.
AlbertsD.S., LiuP.Y., WilczynskiS.P.Randomized trial of pegylated liposomal doxorubicin (PLD) plus carboplatin versus carboplatin in platinum-sensitive (PS) patients with recurrent epithelial ovarian or peritoneal carcinoma after failure of initial platinum-based chemotherapy Southwest Oncology Group Protocol S0200). Gynecol Oncol.2008; 108(1): 90–94.
5.
NakanishiT., AokiD., WatanabeY.A Phase II clinical trial of pegylated liposomal doxorubicin and carboplatin in Japanese patients with platinum-sensitive recurrent ovarian, fallopian tube or primary peritoneal cancer. Jpn J Clin Oncol.2015; 45(5): 422–426.
6.
du BoisA., PfistererJ., BurchardiN.Combination therapy with pegylated liposomal doxorubicin and carboplatin in gynecologic malignancies: A prospective phase II study of the Arbeitsgemeinschaft Gynäekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and Kommission Uterus (AGO-K-Ut). Gynecol Oncol.2007; 107(3): 518–525.
7.
HsiaoS.M., ChenC.A., LinH.H.Phase II trial of carboplatin and distearoylphosphatidylcholine pegylated liposomal doxorubicin (Lipo-Dox) in recurrent platinum-sensitive ovarian cancer following front-line therapy with paclitaxel and platinum. Gynecol Oncol.2009; 112(1): 35–39.
8.
PowerP., StuartG., OzaA.Efficacy of pegylated liposomal doxorubicin (PLD) plus carboplatin in ovarian cancer patients who recur within six to twelve months: A phase II study. Gynecol Oncol.2009; 114(3): 410–414.
9.
RapoportB.L., VorobiofD.A., SlabberC.Phase II study of pegylated liposomal doxorubicin and carboplatin in patients with platinum-sensitive and partially platinum-sensitive metastatic ovarian cancer. Int J Gynecol Cancer.2009; 19(6): 1137–1141.
10.
WeberB., LortholaryA., MayerF.Pegylated liposomal doxorubicin and carboplatin in late-relapsing ovarian cancer: A GINECO group phase II trial. Anticancer Res.2009; 29(10): 4195–4200.
11.
BafaloukosD., LinardouH., AravantinosG.A randomized phase II study of carboplatin plus pegylated liposomal doxorubicin versus carboplatin plus paclitaxel in platinum sensitive ovarian cancer patients: A Hellenic Cooperative Oncology Group study. BMC Med.2010; 8: 3.
12.
MarkmanM., MoonJ., WilczynskiS.Single agent carboplatin versus carboplatin plus pegylated liposomal doxorubicin in recurrent ovarian cancer: Final survival results of a SWOG (S0200) phase 3 randomized trial. Gynecol Oncol.2010; 116(3): 323–325.
13.
KurtzJ.E., KaminskyM.C., FloquetA.Ovarian cancer in elderly patients: Carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in late relapse: A Gynecologic Cancer Intergroup (GCIG) CALYPSO substudy. Ann Oncol.2011; 22(11): 2417–2423.
14.
GladieffL., FerreroA., De RauglaudreG.Carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in partially platinum-sensitive ovarian cancer patients: Results from a subset analysis of the CALYPSO phase III trial. Ann Oncol.2012; 23(5): 1185–1189.
15.
WagnerU., MarthC., LargillierR.Final overall survival results of phase III GCIG CALYPSO trial of pegylated liposomal doxorubicin and carboplatin vs paclitaxel and carboplatin in platinum-sensitive ovarian cancer patients. Br J Cancer.2012; 107(4): 588–591.
16.
MahnerS., MeierW., du BoisA.Carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in very platinum-sensitive ovarian cancer patients: Results from a subset analysis of the CALYPSO phase III trial. Eur J Cancer.2015; 51(3): 352–358.
17.
PignataS., ScambiaG., SavareseA.Carboplatin and pegylated liposomal doxorubicin for advanced ovarian cancer: Preliminary activity results of the MITO-2 phase III trial. Oncology.2009; 76(1): 49–54.
CalvertA.H., NewellD.R., GumbrellL.A.Carboplatin dosage: Prospective evaluation of a simple formula based on renal function. J Clin Oncol.1989; 7(11): 1748–1756.
20.
CockcroftD.W., GaultM.H.Prediction of creatinine clearance from serum creatinine. Nephron.1976; 16(1): 31–41.
21.
CathomasR., HarleA., MeadG.M.Glomerular filtration rate (GFR) in patients with stage I testicular seminoma treated with adjuvant carboplatin: A comparison of six formulae compared to a radioisotope gold standard. J Clin Oncol.2007; 25(18 suppl): abstract 15504.
22.
BoumedienF., ArsenaultY., LeTarteN.Impact of weight and creatinine measurements in carboplatin dosing. J Clin Oncol.2012; 30(15 suppl): abstract e13027.
23.
EkhartC., RodenhuisS., SchellensJ.H.M., BeijnenJ.H., HuitemaA.D.R.Carboplatin dosing in overweight and obese patients with normal renal function. Does weight matter?Cancer Chemother Pharmacol.2009; 64(1): 115–122.
24.
HerringtonJ.D., TranH.T., RiggsM.W.Prospective evaluation of carboplatin AUC dosing in patients with a BMI ≥ 27 or cachexia. Cancer Chemother Pharmacol.2006; 57(2): 241–247.
25.
DevineB.J.Gentamycin therapy. Drug Intell Clin Pharm.1974; 8: 650–655.
26.
KaagD.Carboplatin dose calculation in lung cancer patients with low serum creatinine concentrations using CKDEPI and Cockcroft-Gault with different weight descriptors. Lung Cancer.2013; 79(1): 54–58.
27.
O'CearbhaillR.New guidelines for carboplatin dosing. Gyn Oncol Group Newsletter.2012; (Spring issue): 5–6.
CheungY.W., CradockJ.C., VishnuvajjalaB.R., FloraK.P.Stability of cisplatin, iproplatin, carboplatin, and tetraplatin in commonly used intravenous solutions. Am J Hosp Pharm.1987; 44(1): 124–130.
30.
MyersA.L., ZhangY.P., KawediaJ.D.Stability study of carboplatin infusion solutions in 0.9% sodium chloride in polyvinyl chloride bags. J Oncol Pharm Pract.2016; 22(1): 31–36.
KrisM.G., HeskethP.J., SomerfieldM.R.; American Society of Clinical Oncology. American Society of Clinical Oncology guideline for antiemetics in oncology: Update 2006. J Clin Oncol.2006; 24(18): 2932–2947.
HeskethP.J., BohlkeK., LymanG.H.Antiemetics: American Society of Clinical Oncology Focused Guideline Update. Antiemetics: American Society of Clinical Oncology Focused Guideline Update. J Clin Oncol. Accessed November 2, 2015.
35.
GelingO., EichlerH.G.Should 5-hydroxytryptamine-3 receptor antagonists be administered beyond 24 hours after chemotherapy to prevent delayed emesis? Systematic re-evaluation of clinical evidence and drug cost implications. J Clin Oncol.2005; 23(6): 1289–1294.
36.
TerreyJ.P., AaproM.S.The activity of granisetron in patients who had previously failed ondansetron antiemetic therapy. Eur J Clin Res.1996; 8: 281–288.
37.
CarmichaelJ., KeizerH.J., CupissolD.Use of granisetron in patients refractory to previous treatment with antiemetics. Anticancer Drugs.1998; 9(5): 381–385.
38.
de WitR., de BoerA.C., vd LindenG.H.Effective crossover to granisetron after failure to ondansetron, a randomized double blind study in patients failing ondansetron plus dexamethasone during the first 24 hours following highly emetogenic chemotherapy. Br J Cancer.2001; 85(8): 1099–1101.
39.
SmithIE; the Granisetron Study Group. A dose-finding study of granisetron, a novel antiemetic, in patients receiving cytostatic chemotherapy. J Cancer Res Clin Oncol.1993; 119(6): 350–354.
40.
SoukopM.the Granisetron Study Group. A dose-finding study of granisetron, a novel antiemetic, in patients receiving high-dose cisplatin. Support Care Cancer.1994; 2(3): 177–183.
41.
MartinM.The severity and pattern of emesis following different cytotoxic agents. Oncology.1996; 53(Suppl 1): 26–31.
42.
DuBoisA., VachW., KiechleM.Pathophysiology, severity, pattern, and risk factors for carboplatin-induced emesis. Oncology.1996; 53(Suppl 1): 26–31.
43.
CornelisonT.L., ReedE.Nephrotoxicity and hydration management for cisplatin, carboplatin, and ormaplatin. Gynecol Oncol.1993; 50(2): 147–158.
44.
AlbertsD.S., GarciaD.J.Safety aspects of pegylated liposomal doxorubicin in patients with cancer. Drugs.1997; 54(Suppl 4): 30–35.
45.
CastellsM.C.Hypersensitivity to antineoplastic agents. Curr Pharm Des.2008; 14(27): 2892–2901.
46.
MarkmanM., KennedyA., WebsterK.Clinical features of hypersensitivity reactions to carboplatin. J Clin Oncol.1999; 17(4): 1141–1145.
47.
HesterbergP.E., BanerjiA., OrenE.Risk stratification for desensitization of patients with carboplatin hypersensitivity: Clinical presentation and management. J Allergy Clin Immunol.2009; 123(6): 1262–1267.
48.
LeeC.W., MatulonisU.A., CastellsM.C.Rapid inpatient/outpatient desensitization for chemotherapy hypersensitivity: Standard protocol effective in 57 patients for 255 courses. Gynecol Oncol.2005; 99(2): 393–399.
SmithT.J., KhatcheressianJ., LymanG.H.: 2006 update of recommendations for the use of white blood cell growth factors: An evidence-based clinical practice guideline. J Clin Oncol.2006; 24: 3187–3205.
KintzelP.E., DorrR.T.Anticancer drug renal toxicity and elimination: Dosing guidelines for altered renal function. Cancer Treat Rev.1995; 21(1): 33–64.
53.
AronoffG.R., BennettW.M., BernsJ.S.Drug Prescribing in Renal Failure.5th ed.Philadelphia: American College of Physicians; 2007.
